TY - JOUR
KW - Adult
KW - Antiretroviral Therapy, Highly Active
KW - CD4 Lymphocyte Count
KW - Counseling
KW - Feasibility Studies
KW - Female
KW - HIV Infections/complications/drug therapy/mortality
KW - Humans
KW - Incidence
KW - Indonesia
KW - Male
KW - Methadone/therapeutic use
KW - Opiate Substitution Treatment/methods
KW - Proportional Hazards Models
KW - Substance Abuse, Intravenous/complications/drug therapy/mortality
KW - Ukraine
KW - Vietnam
KW - Viral Load/drug effects
KW - Young Adult
AU - W. C. Miller
AU - I. F. Hoffman
AU - B. S. Hanscom
AU - T. V. Ha
AU - K. Dumchev
AU - Z. Djoerban
AU - S. M. Rose
AU - C. A. Latkin
AU - D. S. Metzger
AU - K. E. Lancaster
AU - V. F. Go
AU - S. Dvoriak
AU - K. R. Mollan
AU - S. A. Reifeis
AU - E. M. Piwowar-Manning
AU - P. Richardson
AU - M. G. Hudgens
AU - E. L. Hamilton
AU - J. Sugarman
AU - S. H. Eshleman
AU - H. Susami
AU - V. A. Chu
AU - S. Djauzi
AU - T. Kiriazova
AU - D. D. Bui
AU - S. A. Strathdee
AU - D. N. Burns
A1 - 
BT - Lancet (London, England)
C5 - Opioids & Substance Use
CP - 10149
CY - England
IS - 10149
JF - Lancet (London, England)
PB - Elsevier Ltd
PP - England
PY - 2018
SN - 1474-547X; 0140-6736
SP - 747
EP - 759
EP - 
T1 - A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study
T2 - Lancet (London, England)
TI - A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study
U1 - Opioids & Substance Use
U2 - 30191830
VL - 392
VO - 1474-547X; 0140-6736
Y1 - 2018
ER -